Exelixis reported $11.87M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 6.68M 1.48M
Akebia Therapeutics AKBA:US $ 7.8M 36.58M
Amgen AMGN:US $ 1609M 28M
AstraZeneca AZN:LN 3824M 1631M
Bayer BAYN:GR € 3887M 659M
Biomarin Pharmaceutical BMRN:US $ 103.54M 23.52M
Bluebird Bio BLUE:US $ 19.7M 4.4M
Bristol Myers Squibb BMY:US $ 2291M 160M
Eisai 4523:JP Y 40621M 1371M
Eli Lilly And LLY:US $ 1430.8M 522.4M
Esperion Therapeutics ESPR:US $ 5.56M 3.76M
Exelixis EXEL:US $ 11.87M 3.01M
Glaxosmithkline GSK:US $ 2822M 303M
IONIS PHARMACEUT IONS:US $ 3M 0.04M
MacroGenics MGNX:US 1.66M 1.64M
Merk MRK:US $ 3056M 14M
Moderna Inc MRNA:US 722M 28M
Nektar Therapeutics NKTR:US $ 5.31M 2.36M
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Novartis NOVN:VX SF 3848M 94M
Pfizer PFE:US $ 9931M 2939M
Puma Biotechnology PBYI:US $ 10.28M 1.69M
Seattle Genetics SGEN:US $ 82.65M 4.56M
Takeda 4502:JP Y 275797M 34533M
Ultragenyx Pharmaceutical RARE:US $ 4.18M 1.04M
YTE INCY:US $ 34.47M 1.84M